Lupin is a global pharma company that develops and commercializes small molecules and biologics. At this meeting, our goals are in-license late-stage novel products (already in phase 3 or preferably beyond) for US, Europe and India.

• For US and Europe, our key therapeutic areas of focus are ophthalmology, pulmonology and neurology.
• For India, our interests are broad including all therapeutic areas.